Asia-Pacific respiratory drug market was $9.8 billion in 2018 and is anticipated to grow at a substantial rate of 7.9% during the forecast period. Major factors that augment the growth of the market include a large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and the significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in life science research coupled with harnessing innovation. The respiratory drug market in the Asia-Pacific region presents future opportunities for growth as the prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing the geriatric population specially in Japan is another major reason for the growing market.

Request a Free Sample of our Asia-Pacific Respiratory Drug Market: https://www.omrglobal.com/request-sample/asia-pacific-respiratory-drug-market

The major economies that are contributing to the regional business growth of the market include China, Japan, India, and others. The Asia-Pacific respiratory drug market is segmented on the basis of the route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the economies of the region such as China, Japan, India, and Others.

A full Report of Asia-Pacific Respiratory Drug Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-respiratory-drug-market

Asia-Pacific Respiratory Drug Market Segmentation

By Route of Administration

• Oral
• Injectable
• Inhalable

By Application

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

By End-User

• Homecare
• Hospitals and Clinics

Regional Analysis

• China
• Japan
• India
• Rest of Asia-Pacific

Company Profiles

• Air Liquide S.A.
• Aradigm Corp.
• AstraZeneca PLC
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Cipla Ltd.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Merck & Co.
• Novartis AG
• Omron Healthcare Inc.
• Pfizer Inc.
• ResMed Corp.
• Savara, Inc.
• Sunovion Pharmaceuticals
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceuticals Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-respiratory-drug-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404